Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
NCT02593123
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Richmond, Virginia, United States
View Trial DetailsNCT Number: NCT03316209
Lymphoid hemopathies are a group of malignant haematological disorders characterized by clonal proliferation of cells of the lymphoid line. Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) are the most frequently encountered features of lymphoid hemopathies. Duriong the last 35 years the prevalence of these pathologies has increased in France but also in most industrialized countries. This increased can't be solely explained by demographic changes and improvements in diagnostic techniques. As a result, the involvement of environmental and professional factors is strongly suspected. Studies have shown that these diseases are associated with some professions or type of activity, including agricultural occupations, and other sectors such as agriculture, printing, woodworking. Some organic solvents and pesticides have been suspected of being risk factors of hematologic malignancies. Based on cohort studies and case-control studies, some of them have been identified by the International Cancer Research Center as associated with the occurrence of NHL with a sufficient or limited level of evidence. One of the difficulties encountered in the analysis of the literature has been the permanent evolution of the international classification of lymphoid hemopathies over the past 30 years. The old epidemiological studies are therefore difficult to interpret. Lymphoid hemopathies cover a range of different conditions, thus it is likely that carcinogens involved vary according to the type of hemopathy. Finally, environmental and occupational exposures to various chemicals and biological agents have evolved over time. The aim of this study is firstly to develop and validate a questionnaire to identify and quantify exposures to nuisances (substances and agents) suspected of being associated with the occurrence of NHL, MM and LLC. In a second time, this questionnaire will be used as a support for the realization of a subsequent case-control study to improve epidemiological knowledge on these diseases.
Looking for future studies?
Notify Me20 year–80 year
All sexes
Observational
CHU Bordeaux, Bordeaux, France
This study is a prospective, multicenter study on patients with a diagnosis of NHL, MM or CLL. All the patients with a diagnosis of NHL, MM or CLL in the participant centers will be purposed to participate. Each patient included will have an interview with a clinical study technician or doctor of occupational medicine. A specific detailed questionnaire has been created for the study. It focuses on specialized professional careers to spread occupational exposures to nuisances (substances and agents) suspected of being associated with NHL, MM or LLC risk. Each questionnaire will be evaluated by a physician expert in occupational disease, to conclude on the parameters exposure to the various suspected carcinogens. The study will cover 300 patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: day 1
included patient will complete a questionnaire (duration: 2 hours). this questionnaire will be interpreted by an expert physician in occupational diseases
Time frame: day 1
Time frame: day 1
Time frame: day 1
Time frame: day 1
Centre Hospitalier Intercommunal Creteil
Other
Acronym: RHELYPRO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02593123
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Richmond, Virginia, United States
View Trial DetailsNCT02129582
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Cleveland, Ohio, United States
View Trial DetailsNCT00145652
Anemia, Blood Protein Disorders
Sundsvall, Sweden
View Trial DetailsNCT04771572
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Chicago, Illinois, United States
View Trial Details